74
96. Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, et al.
Short-term prophylaxis with C1-inhibitor concentrate in
patients with hereditary angioedema prior to surgical
procedures.
J Allergy Clin Immunol.
2010;125(Suppl 2):
AB164.
97. Martinez-Saguer I, Heller C, KreuzW. Continuous infusion
of a pasteurized C1 inhibitor concentrate in patients
with severe hereditary angioedema (HAE).
Eur J Pediatr.
1999;158(Suppl 3):S211-S220.
98. Farkas H, Jakab L, Temesszentandrási G, et al. Hereditary
angioedema: a decade of human C1-inhibitor concentrate
therapy.
J Allergy Clin Immunol.
2007;120(4):941-947.
99. Pastó Cardona L, Bordas Orpinell J, Mercadal Orfila G, et
al. [Prophylaxis and treatment of hereditary and acquired
angioedema at HUB; use of the C1-esterase inhibitor].
Farm Hosp.
2003;27(6):346-352.
100. Bork K. Pasteurized C1 inhibitor concentrate in hereditary
angioedema: pharmacology, safety, efficacy and future
directions.
Expert Rev Clin Immunol.
2008;1:13-20.
101. Schneider L, Hurewitz D, Wasserman R, et al. C1-INH
concentrate for treatment of acutehereditary angioedema:
a pediatric cohort from the I.M.P.A.C.T. studies.
Pediatr
Allergy Immunol.
2013;24(1):54-60.
102. CicardiM, Zingale L, Zanichelli A, et al. C1 inhibitor:molecular
and clinical aspects.
Springer Semin Immun.
2005;27:
286-298.
103. Davis AE III, Mejia P, Lu F. Biological activities of C1 inhibitor.
Mol Immunol.
2008;45:4057-4063.
104. Beinrohr L, Harmat V, Dobó J, et al. C1 inhibitor serpin
domain structure reveals the likely mechanism of heparin
potentiation and conformational disease.
J Biol Chem.
2007;282:21100-21109.
105. Matsushita M, Thiel S, Jensenius JC, et al. Proteolytic
activities of two types of mannosebinding lectin-associated
serine protease.
J Immunol.
2000;165:2637-2642.
106. Davis AE III. Hereditary angioedema: a current state-of-
the-art review, III: mechanisms of hereditary angioedema.
Ann Allergy Asthma Immunol.
2008;100(Suppl 2):S7-S12.
107. Colman RW. Contact activation (kallikreinkinin) pathway:
multiple physiologic and pathophysiologic activities.
In: Colman RW, Marder VJ, Clowes AW, George JN,
Goldhaber SZ, eds.
Hemostasis and Thrombosis: Basic
Principles and Clinical Practice.
5th ed. Philadelphia, Pa:
Lippincott Williams & Wilkins; 2005:107-130.
108. Schousboe I. Binding of activated factor XII to endothelial
cells affects its inactivation by the C1 esterase inhibitor.
Eur J Biochem.
2003;270:111-118.
109. Nussberger J, Cugno M, Armstutz C, et al. Plasma brady-
kinin in angio-oedema.
Lancet.
1998;351(9117):1693-
1697.
110. Davis AE III, Cai S, Liu D. C1 inhibitor: biologic activities that
are independent of protease inhibition.
Immunobiology.
2007;212:313-323.
111. Liu D, Lu F, Qin G, et al. C1 inhibitor-mediated protection
from sepsis.
J Immunol.
2007;179:3966-3972.
112. Gröner A, Nowak T, Schäfer W. Pathogen safety of human
C1 esterase inhibitor concentrate.
Transfusion.
2012;
52(10):2104-2112.
113. Feußner A, Kalina U, Schuermann D, et al. Biochemical
comparison of 4 commercially available C1 esterase
inhibitor concentrates for treatment of hereditary angio-
edema. Presented at: Annual meeting of the American
College of Allergy Asthma & Immunology, November
8-13 2012, Anaheim, CA, United States. Poster number
P227.
